@NielsRHolm Profile picture

Niels R. Holm

@NielsRHolm

MD and trialist. PCI vs CABG. PCI techniques, OCT imaging, imaging based physiology. Enjoy working with the greatest team!

Similar User
Javier Escaned photo

@JEscaned

Carlo Tumscitz photo

@skat_ct

jcspratt photo

@jcspratt

Goran Stankovic, MD, PhD photo

@GoranEBC

EAPCIPresident photo

@EAPCIPresident

Tom Johnson photo

@twj1974

Alessandro Sticchi photo

@Sticchi_Alex

Marco Jean photo

@MarcoJe80135689

Prof. Hector M. Garcia-Garcia photo

@hect2701

Maksymilian Opolski photo

@OpolskiMP

Dr Peter O'Kane photo

@DrPeterOKane

Nieves Gonzalo photo

@NievesGonzalo1

Gabor G Toth photo

@gabor_gt

Stefan Harb photo

@stefan_harb

Valeria Paradies photo

@valeriaparadies

Niels R. Holm Reposted

I'm German. 16 years ago, the EU and US economies were neck and neck. Today, the US economy is 50% larger than the entire EU combined. Here's the devastating truth behind Europe's ongoing economic suicide 🧵:

Tweet Image 1
Tweet Image 2

Niels R. Holm Reposted

Well, I guess I don’t have to say much here — this young man received this ~3.0 mm stent for what seems to be at least ~ 6mm vessel. A year and half ago and now this unsurprisingly happened…. @ACCinTouch @SCAI @TCTMD @mmamas1973 @mirvatalasnag @Pooh_Velagapudi #Image


Morning run along this iconic building designed by a Danish architect🇩🇰 Getting ready for two exciting days with great colleagues at the 2024 Australasian Bifurcation Club meeting #complexPCI #OCTfirst #cardiotwitter

Tweet Image 1

Niels R. Holm Reposted

Diabetic subgroup analysis also confirmed the improvements in target lesion revascularization by IVUS guidance (JACC: Cardiovascular Interventions. 2024 October)


Niels R. Holm Reposted

Great question! There’s likely diminishing returns above a certain threshold of number of cases. Feels somewhat misinterpreted though since Scandinavian i.c. (while retaining work life balance) on average have 3x the number of PCI cases compared with average US colleagues . 😊


Niels R. Holm Reposted

Looking for a statin alternative? If statins aren’t enough to hit your patient's lipid goals, we’ve got you covered! 🌟Check out our latest infographic on non-statin lipid-lowering therapies.📊Discover their efficacy, outcomes, and pros and cons. #Lipids #Prevention #CardioNerds

Tweet Image 1

Niels R. Holm Reposted

"The first #AI supercomputer funded by Ozempic" Danish Centre for AI Innovation novonordiskfonden.dk/en/projects/da… "Gefion"— weighs >30 tons, bigger than a basketball court, 1,528 GPUs, $100 million wsj.com/tech/ai/nvidia… by @bzcohen @nvidia @NVIDIAAI @novonordiskfond @NadiaCarlsten

Tweet Image 1

Niels R. Holm Reposted

Today was the culmination of several years work. The IVIO trial was published in New England Journal of Medicine. Amazing work by Mikael Fink Valentin. Thank you to all physicians and paramedics for including patients.  nejm.org/doi/full/10.10… @LarsWAndersen1


Niels R. Holm Reposted

QFR Did Not Meet Non-inferiority to FFR: FAVOR III Europe Trial Written by @ceciliabahit #TCT24 @CMichaelGibson cardiologynownews.org/qfr-did-not-me…


Niels R. Holm Reposted

Thank you to all attendees, faculty, partners, and the @crfheart team for making #TCT2024 a remarkable success! We’re thrilled to build on this momentum and bring you an even more impactful #TCT2025. @jgranadacrf

🎉 A huge shoutout to all our friends and colleagues who made #TCT2024 unforgettable! 🙌 Your enthusiasm, dedication, and invaluable contributions transformed this meeting into an incredible success. Together, we’re shaping the future of cardiovascular care! 🫀✨ #CardioX



Niels R. Holm Reposted

Do you have a manuscript to submit for publication? #TCT2024 #AHAJournals will consider your original article submission in any format, as long as all files are provided. Learn more about our format-free submission guidance in our new Author Hub: ahajrnls.org/3Z3qp5a


Niels R. Holm Reposted

Full length Lancet article showing “QFR might not be a reasonable alternative to FFR when FFR is available”

Presented today at #TCT2024: Quantitative flow ratio versus fractional flow reserve for coronary revascularisation guidance (FAVOR III Europe): a multicentre, randomised, non-inferiority trial hubs.li/Q02W6crZ0 @TCTConference

Tweet Image 1


Great take on the @FAVORIIITrial by the @TCTMD - including insightful comments by @JoostDaemen #TCT2024 #cardiotwitter @B_Krogsgaard

QFR No Match for FFR in Guiding Revascularizations: FAVOR III Europe dlvr.it/TFv3Sz

Tweet Image 1


Niels R. Holm Reposted

Should angio derived QFR no longer have a Class 1B recommendation given that it did not meet non-inferiority to FFR?


Niels R. Holm Reposted

The FAVOR III Europe trial showed that noninvasive functional testing of intermediate stenoses w/ QFR resulted in more frequent #MACE than FFR-guided #revascularization in patients w/ chronic or acute coronary syndrome. bit.ly/3Uu2JUA #cvACS #TCT2024

Tweet Image 1

Niels R. Holm Reposted

QFR No Match for FFR in Guiding Revascularizations: FAVOR III Europe dlvr.it/TFv3Sz

Tweet Image 1

Niels R. Holm Reposted

Artificial Intelligence-Based Fully Automated Quantitative Coronary Angiography Versus Optical Coherence Tomography Guided PCI (FLASH Trial) | JACC: Cardiovascular Interventions jacc.org/doi/10.1016/j.… #CardioTwitter #TCT24

Tweet Image 1
Tweet Image 2

Niels R. Holm Reposted

Congratulations @NielsRHolm and @B_Krogsgaard for delivering the FAVOR III Europe Trial. Honored to provide the commentary for this presentation @mirvatalasnag @dr_benoy_n_shah @drptca @NickCurzen @drandrewsharp @purviparwani @iamritu @hvanspall @JGrapsa @jgranadacrf

Tweet Image 1
Tweet Image 2
Tweet Image 3
Tweet Image 4

1/x #QFR did not meet non-inferiority to FFR in the @FAVORIIITrial Europe presented by @B_Krogsgaard The 1-year primary EP of death, MI, and unplanned revasc was 6.7% vs 4.2% in favour of FFR. 21% more study-lesions were treated- and 27% more stents were implanted with QFR due…

Tweet Image 1


Niels R. Holm Reposted

FAVOR III Europe trial results are in! 🌍 QFR-based strategy in coronary physiology doesn’t match FFR for clinical outcomes at one year. Findings announced at #TCT2024 and published in @TheLancet thelancet.com/journals/lance… #CardioX #CardioTwitter #CardioEd #CardioResearch

Tweet Image 1

Niels R. Holm Reposted

I am proud of our team work in both conducting and reporting the @FAVORIIITrial Publication is now available online in @TheLancet @NielsRHolm @h_evald

Presented today at #TCT2024: Quantitative flow ratio versus fractional flow reserve for coronary revascularisation guidance (FAVOR III Europe): a multicentre, randomised, non-inferiority trial hubs.li/Q02W6crZ0 @TCTConference

Tweet Image 1


Loading...

Something went wrong.


Something went wrong.